Supplemental Data Set

Characteristics of the cohort underpinning this cross-sectional study Methods Part A: Metabolomics profiling and data preprocessing Part B: Drug deconfounding analysis Part C: Transcriptomics profiling and data preprocessing Table S1. Diagnosis and pharmacological treatment of 19 HIV-positive individuals with cardiovascular disease Table S2. Classification of metabolomic features as dysmetabolic, escalation, de-escalation and CVD Table S3. Classification of transcriptome features as dysmetabolic, escalation, de-escalation and CVD Table S4. Classification of metabolomic features as dysmetabolic, escalation, de-escalation and CVD as well as comparison based on the cardiometabolic disease spectrum Table S5. Pathway enrichment analysis of metabolome markers in the cardiometabolic disease spectrum in people living with HIV Fig. S1 Operational classification of metabolome features from the perspective of CVD pathology Fig. S2 Methodology employed for the classification of transcriptome features in the cross-sectional study Fig. S3 Transcriptome features associated with CVD and its dysmetabolic pre-morbidities Fig. S4 Functional enrichment analysis of transcriptome markers